The global GLP-1 receptor agonist market is expected to record a CAGR of 6.1% during 2021-2028 and was estimated to be valued at US$ 19,253.8 million in 2021.
Market Drivers
Approval and launch of new products is expected to propel growth of the global GLP-1 receptor agonist market over the forecast period. For instance, the U.S. Food and Drug Administration approved, in January 2020, the label expansion of Ozempic (semaglutide) from Novo Nordisk A/S for reducing the risk of heart attack, stroke and death in type 2 diabetes and cardiovascular disease patients.
To Get More Business Strategies Sample Copy of Report @ https://www.coherentmarketinsights.com/insight/request-sample/4632
Moreover, high prevalence of diabetes is also expected to propel growth of the global GLP-1 receptor agonist market over the forecast period. For instance, the prevalence of diabetes in India was 11.8% during 2015-2019, according to the National Diabetes and Diabetic Retinopathy Survey report published in October 2019. According to the same source the prevalence of known diabetes cases was 8.0% and new diabetes cases was 3.8% during the period.
Covid-19 Impact Analysis
A study conducted in the U.K during March 16, 2020 to April 26, 2020 reported that around 8.6% of COVID-19 patients were associated with inadequate physical activity while 29.5% of COVID-19 patients were associated with overweight and obesity. Such scenario is expected to boost demand for GLP-1 receptor agonist.
Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables& Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-pdf/4632
Market Trends
Major players operating in the global GLP-1 receptor agonist market are focused on adopting partnership strategies to enhance their market share. For example, in August 2020, Hanmi Pharm. Co., Ltd. partnered with Merck KGaA for manufacturing and commercialization of its glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist for the treatment of non-alcoholic steatohepatitis.
Key Players
Major players operating in the global GLP-1 receptor agonist market include, Amylin Pharmaceuticals, Inc., Amgen Inc., AstraZeneca, Eli Lilly and Company, GlaxoSmithKline plc, Hanmi Pharm. Co., Ltd., Intarcia Therapeutics, Inc., Innovent Biologics, Jiangsu Hengrui Medicine Co., Novo Nordisk A/S, PegBio Co., Ltd., Pfizer Inc., Sanofi, Sun Pharmaceuticals Industries Ltd., and 9 Meters Biopharma, Inc.
Key Developments
Major players operating in the global GLP-1 receptor agonist market are focused on approval and launch of new products to expand their product portfolio. For example, the U.S. Food and Drug Administration approvedGLP-1 receptor agonist drug Saxenda (liraglutide) from Novo Nordisk A/S, for the treatment of obesity in children of age 12 and above, in December 2020.
Purchase This Premium Report With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/4632
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Pipeline Analysis
- PEST Analysis
- Regulatory Scenario
- Market Trends
- Key Highlights
- Reimbursement Scenario
- Mergers & Acquisitions
- Market Dynamics
- Global GLP-1 Receptor Agonist Market – Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- Impact on Clinical Trials and Drug Development
- Government Initiatives
- Global GLP-1 Receptor Agonist Market, By Drug Class, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Exenatide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Liraglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Dulaglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Lixisenatide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Albiglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Semaglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Introduction
- Global GLP-1 Receptor Agonist Market, By Route of Administration, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Introduction
- Global GLP-1 Receptor Agonist Market, By Application, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Type 2 Diabetes Mellitus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Obesity
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Liver Cirrhosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Non-alcoholic Steatohepatitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Others (Others include Cardiovascular Disease and Type-1 Diabetes)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Introduction
- Global GLP-1 Receptor Agonist Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/glp-1-receptor-agonist-market-3884
About US:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837